{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T06:40:22Z","timestamp":1653547222360},"reference-count":6,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,4,1]]},"DOI":"10.1200\/jco.2001.19.7.2107","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:41:13Z","timestamp":1487918473000},"page":"2107-2108","source":"Crossref","is-referenced-by-count":10,"title":["Steroidal Side Effects of Exemestane"],"prefix":"10.1200","volume":"19","author":[{"given":"Jean-Marc A.","family":"Nabholtz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-088646A","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.7.1399"},{"key":"R2-088646A","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006048722559"},{"key":"R3-088646A","unstructured":"Johannessen  DC,   Engan  T,   Di Salle  E,  et al:  Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal inhibitor, in postmenopausal breast cancer patients:   A phase I study.   Clin Cancer Res 3:  1101,1997-1108,"},{"key":"R4-088646A","doi-asserted-by":"crossref","unstructured":"Th\u00fcrlimann  B,   Paridaens  R,   Serin  D,  et al:  Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide:   A phase II multicentre multinational study.   Eur J Cancer 33:  1757,1997-1773,","DOI":"10.1016\/S0959-8049(97)00283-9"},{"key":"R5-088646A","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3418"},{"key":"R6-088646A","unstructured":"Paridaens  R,   Dirix  L,   Nooij  M,  et al:  Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (PTS):   Results of a randomized phase II trial.   Proc Am Soc Clin Oncol 19:  83a,2000  (abstr 316)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.7.2107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:32:56Z","timestamp":1653514376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.7.2107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,4,1]]}},"alternative-id":["10.1200\/JCO.2001.19.7.2107"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.7.2107","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4,1]]}}}